介绍：癌抗原19-9指一种与胰腺癌、胆囊癌、结肠癌和胃癌等相关的肿瘤标志物，又称胃肠道相关抗原。癌抗原19-9对胰腺癌有较高的灵敏度和较好的特异性，其阳性率在85%-95%之间，且随手术后与病情好转而降低。
CA19-9是糖抗原的一种，其水平升高大多预示有胰腺炎、肝硬化、糖尿病、消化道肿瘤的可能。
CA19-9的定标标准值:0-40之间(单位:kU/L)
糖链抗原19-9升高见于:
1. 大部分胰腺癌患者血清CA19-9水平明显增高;
2. 肝胆系癌、胃癌、结直肠癌的CA19-9水平也会升高;
3. 低浓度增高、糖链抗原19-9升高可见于慢性胰腺炎、胆石症、肝硬化、肾功能不全、糖尿病等。
临床应用：
CA19-9是胰腺癌和结、直肠癌的标志物，血清癌抗原19-9可作为胰腺癌，胆囊癌等恶性肿瘤的辅助诊断指标。胚胎期胎儿的胰腺、胆囊、肝、肠等组织存在这种抗原，正常人体组织中含量很低；在消化道恶性肿瘤，尤其是胰腺癌、胆囊癌病人血清中，癌抗原19-9含量明显增高，但早期诊断价值不大，主要作为病情监测和预示复发的指标。此外，对消化道疾病鉴别诊断（如胰腺癌与胰腺炎。胃癌与胃溃疡）亦有一定价值。
增高：见于胰腺癌、胆囊癌、胃癌、结肠癌、肝癌等;急性胰腺炎、胆囊炎、肝炎等也有不同程度的升高。
名称：CA19-9（癌抗原19-9）肿瘤标志物相关抗体
别名：CA19-9（癌抗原19-9）肿瘤标志物，CA199，Carbohydrate antigen199, Carbohydrate antigen 19-9，癌抗原19-9，Anti CA19-9
链接：https://www.antibodysystem.com/index/search?wd=CA19-9
其他产品：
Anti-Human CA19-9/CA199 Monoclonal Antibody (1A297) (MHK33901)
Anti-Human CA19-9/CA199 Monoclonal Antibody (1A298) (MHK33902)
Anti-Human CA19-9/CA199 Monoclonal Antibody (1A299) (MHK33903)
Anti-Human CA19-9/CA199 Monoclonal Antibody (1A300) (MHK33904)
Anti-sLea/CA19-9 Antibody (1116NS19.9) (FHK33910)
Anti-sLea/CA19-9 Antibody (7E3#) (FHK33920)
InVivoMAb Anti-sLea/CA19-9 Antibody (Iv0123) (VHK33901)
Anti-sLea/CA19-9 Antibody (SAA0808) (RHK33901)
Research Grade Anti-Human CA19-9/Sialyl Lewis A (sLe A) Antibody (MVT-5873) (DHK33901)
形式：Liquid
纯度：>95%
用途范围：仅用于科研
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
AntibodySystem：
AntibodySystem是由法国专家团队创立的科研试剂品牌，产品管线覆盖各种病毒研究蛋白/抗体质控品、Invivo功能性抗体，流式抗休、抗药药物靶点蛋白以及其他活性蛋白、PEG抗体，磷酸化抗体、抗DNA抗体、小分子抗体、RUO ELISA试剂盒、生物类似物。
佰乐博生物：法国Antibodysystem品牌亚洲区独家运营代理商
免费热线：027-65279366 /18108604356
QQ：2663991332
咨询邮箱：products@biolabreagent.com
选购商城：https://www.antibodysystem.com
微信公众平台：佰乐博生物Biolab Reagents
参考文献：
CA 19-9: Biochemical and Clinical Aspects. PMID: 26530370
Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. PMID: 29282264
CA19-9 and CEA biosensors in pancreatic cancer. PMID: 38246211
[CA19-9]. PMID: 10778164
Monitoring Ca19-9 during pancreatic cyst surveillance: Better safe than sorry? PMID: 37573577
[CA19-9: more than just a biomarker?]. PMID: 31931544
CA19-9: the Italian experience. PMID: 7846014
Preoperative CA19-9 and GGT ratio as a prognostic indicator in ampullary carcinoma. PMID: 36915042
Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis. PMID: 26576628
[Elevated CA19-9 levels; not always cancer]. PMID: 33651490
The clinical significance of elevated levels of serum CA 19-9. PMID: 15190651
CA19-9 With Two-stage Resection Is Useful for Conversion Surgery in PDAC With Synchronous Oligometastases. PMID: 37909951
Extremely high serum CA19-9 level along with elevated D-dimer in assisting detection of ruptured ovarian endometriosis. PMID: 35733415
Ratio of CA19-9 Level to Total Tumor Volume as a Prognostic Predictor of Pancreatic Carcinoma After Curative Resection. PMID: 35138217
CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts. PMID: 30466797
Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. PMID: 27692554
CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer. PMID: 29038848
Electrochemical Immunoassay for Tumor Marker CA19-9 Detection Based on Self-Assembled Monolayer. PMID: 35889454
Glycoprotein CA19.9-specific monoclonal antibodies recognize sialic acid-independent glycotope. PMID: 29072130
Platelet-to-lymphocyte ratio and CA19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer. PMID: 31000337
CA19-9-producing transitional cell carcinoma of the renal pelvis: a case report. PMID: 11329962
High level of tumor marker CA19-9 returned to normal after cholecystectomy in calculous cholecystitis patients. PMID: 36644950
Prognostic Relevance of PDL1 and CA19-9 Expression in Gallbladder Cancer vs. Inflammatory Lesions. PMID: 36826082
High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma. PMID: 30591483
[CA19-9 has no value as a tumor marker in obstructive jaundice]. PMID: 10065510
CA19-9 is a significant prognostic factor in stage III gastric cancer patients undergoing radical gastrectomy. PMID: 38263014
Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies. PMID: 34119488
Predictive Value of Preoperative Serum CA19-9 on Margin Status. PMID: 31638508
The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis. PMID: 33047181
Combination of preoperative CA19-9 levels, cell differentiation, and age predicts survival for patients with gastric cancer before surgery. PMID: 34889247
[Bronchioloalveolar carcinoma producing CA19-9]. PMID: 21682047
A Rare Cause of Elevated Serum CA19-9. PMID: 32828817
Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. PMID: 28803454
[CA19-9 in intrahepatic cholangiocarcinoma : A diagnostic and prognostic armamentarium?]. PMID: 29644426
SERS-based immunoassay and degradation of CA19-9 mediated by gold nanowires anchored magnetic-semiconductor nanocomposites. PMID: 33265038
Comment re: "Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping". PMID: 28434838
Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. PMID: 22411488
A Case of Pseudoelevation of Serum CA19-9 Level. PMID: 38213206
The implication of tumor biomarker CA19-9 in the diagnosis of intracranial epidermoid cyst. PMID: 27793056
Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. PMID: 21601881
